XOMA Royalty Corporation

XOMA Royalty Corporation operates as a biotech royalty aggregator in the US and Asia Pacific. It has a portfolio of economic rights to milestone and royalty payments from partnered therapeutics. The company also focuses on early-stage clinical assets with commercial sales potential licensed to partners. Additionally, it acquires late-stage clinical or commercial asset revenue streams.

Overview

Sector

Biotechnology

Target Price

125.2 USD

Current Price

32.0 USD

Potential

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	15.2
EV/EBITDA	7.2
Price/Free Cash Flow'	16.7
ROIC	18.3%
Net Debt/EBITDA	0.2

XOMA Royalty Corporation

Overview

Strengths

Weaknesses

Key Financial Data